Twist Bioscience Prices Upsized $300M Public Offering

What Happened

• Twist Bioscience Corporation announced on August 4–5, 2026 that it entered into an underwriting agreement to sell common stock in a public offering. The offering was priced at $96.00 per share.
• The Company agreed to sell 3,125,000 shares to the underwriters and the underwriters exercised their 30‑day option on August 5, 2026 to purchase an additional 468,750 shares, for a total of 3,593,750 shares offered. The offering was upsized and priced at $300.0 million; net proceeds are expected to be approximately $327.1 million after underwriting discounts, commissions and estimated offering expenses. The offering is expected to close on or about August 6, 2026.
• The offering was conducted under the Company’s automatic shelf registration statement on Form S-3 and was announced in press releases dated August 4, 2026 (initial $250M proposal and the priced upsized $300M offering). Lead representatives include Goldman Sachs, William Blair, Leerink Partners and Guggenheim.

Key Details

• Offering price: $96.00 per share (less underwriting discount and commissions).
• Shares sold: 3,125,000 initial shares + 468,750 option shares = 3,593,750 total shares.
• Expected net proceeds: approximately $327.1 million (after discounts, commissions and expenses).
• Timeline & filings: Underwriting Agreement dated August 4, 2026; option exercised August 5, 2026; expected close on or about August 6, 2026; offering made under Form S-3 (No. 333-296897).

Why It Matters

• This is a material capital raise: the offering will increase the number of outstanding common shares and provide roughly $327.1M in cash resources to the company. For investors, that means dilution from newly issued shares and additional liquidity on Twist’s balance sheet to fund operations, growth, or other corporate purposes disclosed in offering materials.
• The transaction was completed through an upsized, underwritten public offering with the underwriters exercising their full option, signaling demand sufficient to sell the additional shares at the priced level. Investors should review the company’s prospectus and related filings for how the net proceeds will be used and monitor the closing for the exact timing and share issuance.